NextPlat (NXPL) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 09, 2024
Document Information [Line Items]
Entity Central Index Key	0001058307
Entity Registrant Name	NextPlat Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-40447
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	65-0783722
Entity Address, Address Line One	3250 Mary St., Suite 410
Entity Address, City or Town	Coconut Grove
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33133
City Area Code	305
Local Phone Number	560-5355
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,973,146
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	NXPLW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	NXPL
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 24,877,000	$ 26,307,000
Accounts receivable, net	10,369,000	8,923,000
Receivables - other, net	1,013,000	1,846,000
Inventories, net	4,701,000	5,135,000
Unbilled revenue	206,000	189,000
VAT receivable	333,000	342,000
Prepaid expenses	273,000	640,000
Notes receivable due from related party	265,000	256,000
Total Current Assets	42,037,000	43,638,000
Property and equipment, net	3,694,000	3,989,000
Goodwill	156,000	731,000
Intangible assets, net	4,564,000	14,423,000
Operating right of use assets, net	887,000	1,566,000
Finance right-of-use assets, net	18,000	22,000
Deposits	39,000	39,000
Prepaid expenses, net of current portion	66,000	61,000
Total Other Assets	5,730,000	16,842,000
Total Assets	51,461,000	64,469,000
Current Liabilities
Accounts payable and accrued expenses	11,894,000	13,176,000
Contract liabilities	142,000	42,000
Notes payable	205,000	312,000
Due to related party	23,000	18,000
Operating lease liabilities	380,000	532,000
Finance lease liabilities	13,000	18,000
Income taxes payable	93,000	139,000
Total Current Liabilities	12,750,000	14,237,000
Long Term Liabilities:
Long-term portion of notes payable	1,120,000	1,211,000
Operating lease liabilities, net of current portion	619,000	929,000
Finance lease liabilities, net of current portion	0	5,000
Total Liabilities	14,489,000	16,382,000
Commitments and Contingencies
Equity
Preferred stock ($0.0001 par value; 3,333,333 shares authorized)	0	0
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,973,146 and 18,724,596 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)	2,000	2,000
Additional paid-in capital	68,348,000	67,170,000
Accumulated deficit	(41,717,000)	(34,925,000)
Accumulated other comprehensive loss	(99,000)	(63,000)
Equity attributable to NextPlat Corp stockholders	26,534,000	32,184,000
Equity attributable to non-controlling interests	10,438,000	15,903,000
Total Equity	36,972,000	48,087,000
Total Liabilities and Equity	$ 51,461,000	$ 64,469,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,333,333	3,333,333
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,973,146	18,724,596
Common stock, shares outstanding (in shares)	18,973,146	18,724,596

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 16,989	$ 2,957	$ 34,482	$ 5,834
Cost of revenue	11,183	2,113	23,867	4,369
Gross profit	5,806	844	10,615	1,465
Operating expenses:
Selling, general and administrative	2,218	2,519	4,220	3,308
Salaries, wages and payroll taxes	2,785	968	5,409	1,556
Impairment loss	9,792	0	9,924	0
Professional fees	1,004	544	1,989	865
Depreciation and amortization	903	168	1,810	330
Total operating expenses	16,702	4,199	23,352	6,059
Loss before other (income) expense	(10,896)	(3,355)	(12,737)	(4,594)
Other (income) expense:
Gain on sale or disposal of property and equipment	0	0	(1)	0
Interest expense	19	5	41	10
Interest earned	(197)	(172)	(412)	(183)
Other income	0	(266)	0	(316)
Foreign currency exchange rate variance	5	(40)	31	(69)
Total other income	(173)	(473)	(341)	(558)
Loss before income taxes and equity in net loss of affiliate	(10,723)	(2,882)	(12,396)	(4,036)
Income taxes	(20)	(52)	(47)	(52)
Loss before equity in net loss of affiliate	(10,743)	(2,934)	(12,443)	(4,088)
Equity in net loss of affiliate	0	(1,407)	0	(1,440)
Net loss	(10,743)	(4,341)	(12,443)	(5,528)
Net loss attributable to non-controlling interest	5,432	0	5,652	0
Net loss attributable to NextPlat Corp	(5,311)	(4,341)	(6,791)	(5,528)
Comprehensive loss:
Net loss	(10,743)	(4,341)	(12,443)	(5,528)
Foreign currency loss	(27)	(12)	(9)	(35)
Comprehensive loss	(10,770)	(4,353)	(12,452)	(5,563)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,311)	$ (4,341)	$ (6,791)	$ (5,528)
Basic weighted average common shares outstanding (in shares)	18,824	18,072	18,774	16,254
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.28)	$ (0.24)	$ (0.36)	$ (0.34)
Product [Member]
Revenue	$ 14,030	$ 2,957	$ 28,150	$ 5,834
Cost of revenue	11,120	2,113	23,741	4,369
Service [Member]
Revenue	2,959	0	6,332	0
Cost of revenue	$ 63	$ 0	$ 126	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	April 2023 Private Placement [Member] Common Stock [Member]	April 2023 Private Placement [Member] Additional Paid-in Capital [Member]	April 2023 Private Placement [Member] Retained Earnings [Member]	April 2023 Private Placement [Member] AOCI Attributable to Parent [Member]	April 2023 Private Placement [Member] Parent [Member]	April 2023 Private Placement [Member] Noncontrolling Interest [Member]	April 2023 Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022								14,402
Balance at Dec. 31, 2022								$ 1	$ 56,963	$ (31,147)	$ (41)	$ 25,776	$ 0	$ 25,776
Stock-based compensation in connection with restricted stock awards (in shares)								39
Stock-based compensation in connection with restricted stock awards								$ 0	61	0	0	61	0	61
Comprehensive loss								0	0	0	(23)	(23)	0	(23)
Net loss								$ 0	0	(1,187)	0	(1,187)	0	(1,187)
Balance (in shares) at Mar. 31, 2023								14,441
Balance at Mar. 31, 2023								$ 1	57,024	(32,334)	(64)	24,627	0	24,627
Balance (in shares) at Dec. 31, 2022								14,402
Balance at Dec. 31, 2022								$ 1	56,963	(31,147)	(41)	25,776	0	25,776
Net loss														(5,528)
Balance (in shares) at Jun. 30, 2023								18,700
Balance at Jun. 30, 2023								$ 2	65,171	(36,675)	(76)	28,422	0	28,422
Balance (in shares) at Mar. 31, 2023								14,441
Balance at Mar. 31, 2023								$ 1	57,024	(32,334)	(64)	24,627	0	24,627
Stock-based compensation in connection with options granted								$ 0	781	0	0	781	0	781
Stock-based compensation in connection with restricted stock awards (in shares)								725
Stock-based compensation in connection with restricted stock awards								$ 0	1,183	0	0	1,183	0	1,183
Comprehensive loss								0	0	0	(12)	(12)	0	(12)
Net loss								$ 0	0	(4,341)	0	(4,341)	0	(4,341)
Stock-based compensation in connection with options granted (in shares)								105
Issuance of common stock related to exercise of warrants								$ 0	184	0	0	184	0	184
Issuance of common stock related offering (in shares)	3,429
Issuance of common stock related offering	$ 1	$ 5,999	$ 0	$ 0	$ 6,000	$ 0	$ 6,000
Balance (in shares) at Jun. 30, 2023								18,700
Balance at Jun. 30, 2023								$ 2	65,171	(36,675)	(76)	28,422	0	28,422
Balance (in shares) at Dec. 31, 2023								18,725
Balance at Dec. 31, 2023								$ 2	67,170	(34,925)	(63)	32,184	15,903	48,087
Stock-based compensation in connection with options granted								$ 0	160	0	0	160	0	160
Stock-based compensation in connection with restricted stock awards (in shares)								0
Stock-based compensation in connection with restricted stock awards								$ 0	387	0	0	387	65	452
Capital contribution of non-controlling interests								0	0	0	0	0	122	122
Comprehensive loss								0	0	0	(27)	(27)	0	(27)
Net loss								$ 0	0	(1,481)	0	(1,481)	(220)	(1,701)
Balance (in shares) at Mar. 31, 2024								18,725
Balance at Mar. 31, 2024								$ 2	67,717	(36,406)	(90)	31,223	15,870	47,093
Balance (in shares) at Dec. 31, 2023								18,725
Balance at Dec. 31, 2023								$ 2	67,170	(34,925)	(63)	32,184	15,903	48,087
Net loss														(12,443)
Balance (in shares) at Jun. 30, 2024								18,973
Balance at Jun. 30, 2024								$ 2	68,348	(41,717)	(99)	26,534	10,438	36,972
Balance (in shares) at Mar. 31, 2024								18,725
Balance at Mar. 31, 2024								$ 2	67,717	(36,406)	(90)	31,223	15,870	47,093
Stock-based compensation in connection with options granted								$ 0	159	0	0	159	0	159
Stock-based compensation in connection with restricted stock awards (in shares)								200
Stock-based compensation in connection with restricted stock awards								$ 0	387	0	0	387	0	387
Comprehensive loss								0	0	0	(9)	(9)	0	(9)
Net loss								$ 0	0	(5,311)	0	(5,311)	(5,432)	(10,743)
Stock-based compensation in connection with options granted (in shares)								0
Issuance of common stock related to exercise of warrants (in shares)								48
Issuance of common stock related to exercise of warrants								$ 0	85	0	0	85	0	85
Balance (in shares) at Jun. 30, 2024								18,973
Balance at Jun. 30, 2024								$ 2	$ 68,348	$ (41,717)	$ (99)	$ 26,534	$ 10,438	$ 36,972

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,443,000)	$ (5,528,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	399,000	317,000
Change in provision for doubtful accounts	(54,000)	0
Amortization of intangible assets	1,398,000	12,500
Amortization of right-of-use assets - operating leases	244,000	98,000
Amortization of right-of-use assets - finance leases	13,000	0
Write-off of right of use asset	111,000	0
Equity in net loss of affiliate	0	1,440,000
Stock-based compensation	1,158,000	2,025,000
Impairment loss	9,924,000	0
Gain on sale or disposal of property and equipment	(1,000)	0
Accounts receivable	(513,000)	(205,000)
Inventories	571,000	(780,000)
Unbilled revenue	(17,000)	(34,000)
Prepaid expense	374,000	(302,000)
Notes receivable	16,000	0
VAT receivable	9,000	0
Accounts payable and accrued expenses	(1,349,000)	(234,000)
Operating lease liabilities	(273,000)	(87,000)
Income taxes payable	(46,000)	67,000
Contract liabilities	100,000	22,000
Liabilities from discontinued operations	0	(112,000)
Net cash used in operating activities	(379,000)	(3,300,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(124,000)	(103,000)
Capital contributions to equity method investee	0	(1,000,000)
Proceeds from sale or disposal of property and equipment	1,000	0
Net cash used in investing activities	(981,000)	(1,103,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable, related party, net	0	(9,000)
Proceeds from common stock offering	0	6,000,000
Proceeds from exercise of warrants	85,000	184,000
Capital contribution of non-controlling interest	122,000	0
Payments on finance lease liabilities	(13,000)	0
Repayments of notes payable	(228,000)	(22,000)
Net cash (used in) provided by financing activities	(34,000)	6,153,000
Effect of exchange rate on cash	(36,000)	(35,000)
Net decrease in cash	(1,430,000)	1,715,000
Cash beginning of period	26,307,000	18,891,000
Cash end of period	24,877,000	20,606,000
SUPPLEMENTAL CASH FLOW INFORMATION
Interest	371,000	173,000
Income taxes	74,000	0
Outfitter Satellite, Inc. [Member]
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired in acquisition of Outfitter Satellite subsidiary	236,000	0
Cash paid in acquisition of Outfitter Satellite subsidiary	$ (1,094,000)	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations.	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	1. The term “Company” refers to NextPlat Corp and its wholly-owned, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Web3 Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not On April 1, 2024, Progressive Care Inc.: Our controlled subsidiary, Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no Florida Sunshine Brands, LLC: Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company and incorporated December 6, 2023. Plan of Reorganization - Progressive Care Merger: On April 12, 2024, Merger Agreement Merger Sub Merger The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three The Company’s shareholders will consider a proposal to approve the Merger at the Company’s annual meeting which is set to occur on September 13, 2024. July 29, 2024

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The accompanying Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2023 10 not 2023 10 not Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. Business acquisition of Outfitter Satellite, Inc. On March 25, 2024, fitter Satellite, Inc. (“Outfitter”). Th April 1, 2024. Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar. The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 1 10 December 31, 2023 no six June 30, 2024 Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $4.4 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000. Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the six June 30, 2024 six June 30, 2023 December 31, 2023 Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At June 30, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024, Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not Subsequent Events The Company has evaluated subsequent events through August 13, 2024

Note 4 - Fair Value

Note 4 - Fair Value	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Identifiable Intangible Assets The initial recognition of Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3 The initial recognition of the Outfitter identifiable intangible assets, resulting from the acquisition on April 1, 2024, 3

Note 5 - Business Acquisition -

Note 5 - Business Acquisition - Provisional	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 5. On March 25, 2024, fitter. Th April 1, 2024. Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar. Final purchase accounting adjustments may may not 12 The following table summarizes the consideration transferred to acquire Outfitter and the amounts of identified assets acquired and liabilities assumed at the acquisition date (in thousands): Purchase Price Allocation (in thousands) Total purchase consideration $ 1,094 Identifiable net assets acquired - Provisional: Cash $ 236 Accounts receivable, net 73 Inventory 137 Prepaid expenses 11 Property and equipment, net 5 Right of use assets, net 109 Intangible assets, net: Trade name (1) 185 Customer records (2) 415 Accounts payable and accrued expenses (124 ) Notes payable and accrued interest - current portion (53 ) Lease liabilities - current portion (56 ) Deferred tax liabilities (3) (145 ) Net assets acquired $ 793 Goodwill $ 301 ( 1 ( 2 ( 3 no not April 1, 2024, April 1, 2024 The goodwill is attributable to the workforce of the acquired business and the significant synergies expected to arise after NextPlat’s acquisition of Outfitter. The goodwill is not The initial recognition of Outfitter's identifiable intangible assets, resulting from the acquisition on April 1, 2024, 3 1 2 3 4 5 6 7 8 9

Note 6 - Revenue

Note 6 - Revenue	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 6. e-Commerce r The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third All pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, are charged at the time of the settlement of a pharmacy claim. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): Three Months Ended June 30, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 10,521 $ - e-Commerce revenue 3,512 2,957 Sub total 14,033 2,957 Revenues from services: Pharmacy 340B contract revenue 2,956 - Revenues, net $ 16,989 $ 2,957 Six Months Ended June 30, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 21,845 $ - e-Commerce revenue 6,377 5,834 Sub total 28,222 5,834 Revenues from services: Pharmacy 340B contract revenue 6,260 - Revenues, net $ 34,482 $ 5,834

Note 7 - Loss Per Share

Note 7 - Loss Per Share	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 7. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not The components of basic and diluted EPS were as follows (in thousands, except per share data). Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (5,311 ) $ (4,341 ) $ (6,791 ) $ (5,528 ) Basic weighted average common shares outstanding 18,824 18,072 18,774 16,254 Potentially dilutive common shares - - - - Diluted weighted average common shares outstanding 18,824 18,072 18,774 16,254 Weighted average loss per common share - basic and diluted $ (0.28 ) $ (0.24 ) $ (0.36 ) $ (0.34 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 9 240 60 175 Common stock purchase warrants - 1,419 - 583 9 1,659 60 758

Note 8 - Accounts Receivable

Note 8 - Accounts Receivable	6 Months Ended
	Jun. 30, 2024
Accounts Receivable [Member]
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 8. At June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 10,587 $ 9,195 Less: allowance for doubtful accounts (218 ) (272 ) Accounts receivable – trade, net $ 10,369 $ 8,923 The Company decreased the allowance for credit losses in the amount of approximately $54,000 and $0 for the six June 30, 2024 2023 Accounts receivable – trade, net for the Company as of January 1, 2023 June 30, 2023

Note 9 - Inventory

Note 9 - Inventory	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 9. At June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 4,747 $ 5,195 Less reserve for obsolete inventory (46 ) (60 ) Total $ 4,701 $ 5,135

Note 10 - VAT Receivable

Note 10 - VAT Receivable	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
VAT Accounts Receivable [Text Block]	Note 10. On January 1, 2021, June 30, 2024 December 31, 2023

Note 11 - Prepaid Expenses

Note 11 - Prepaid Expenses	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Prepaid Expenses [Text Block]	Note 11. Prepaid expenses current and long term amounted to approximately $273,000 and $66,000, respectively at June 30, 2024 December 31, 2023

Note 12 - Property and Equipmen

Note 12 - Property and Equipment, Net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 12. Property and equipment, net consisted of the following (in thousands): June 30, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 603 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 172 124 Computer equipment 117 117 Rental equipment 80 60 Appliques 2,160 2,160 Website development 615 587 Construction in progress - 22 Property and equipment gross 6,590 6,492 Less: accumulated depreciation (2,896 ) (2,503 ) Property and equipment, net $ 3,694 $ 3,989 Depreciation expense was approximately $399,000 and $317,000 for the six June 30, 2024 2023

Note 13 - Goodwill and Intangib

Note 13 - Goodwill and Intangible Assets, net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 13. Goodwill During the three June 30, 2024, third 3 The following table reflects changes in the carrying amount of goodwill during the periods presented by reportable segments (in thousands): e-Commerce Operations Healthcare Operations Total Goodwill, net as of December 31, 2023 $ - $ 731 $ 731 Changes in Goodwill during the year period ended June 30, 2024: Goodwill acquired 301 - 301 Deferred tax effect of intangible basis difference (1) (145 ) - (145 ) Impairment loss - (731 ) (731 ) Goodwill, net as of June 30, 2024 $ 156 $ - $ 156 ( 1 Intangibles During the three June 30, 2024, not not third 3 three June 30, 2024 ( four Intangible assets, net consisted of the following (in thousands): June 30, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 2,447 $ — $ 2,447 Trade names 1,530 — 1,530 Developed technology — — - Customer Contracts 850 (263 ) 587 Total intangible assets $ 4,827 $ (263 ) $ 4,564 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 A summary of the changes to the gross carrying amount, accumulated amortization, and net book value of total intangible assets by reporting unit during the six June 30, 2024 e-Commerce Operations Healthcare Operations Total Balances at December 31, 2023: Gross amount $ 250 $ 15,710 $ 15,960 Accumulated amortization (225 ) (1,312 ) (1,537 ) Net amount 25 14,398 14,423 Changes during the six months ended June 30, 2024: Acquisition 600 — 600 Accumulated amortization expense (38 ) (1,360 ) (1,398 ) Impairment - gross amount — (11,733 ) (11,733 ) Impairment - accumulated amortization — 2,672 2,672 Net amount 562 (10,421 ) (9,859 ) Balances at June 30, 2024: Gross amount 850 3,977 4,827 Accumulated amortization (263 ) — (263 ) Net amount $ 587 $ 3,977 $ 4,564 Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the six June 30, 2024 2023 Year Amount 2024 (remaining six months) $ 560 2025 1,096 2026 1,096 2027 1,096 2028 600 Thereafter 116 Total $ 4,564

Note 14 - Accounts Payable and

Note 14 - Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 14. Accounts payable and accrued expenses consisted of the following (in thousands): June 30, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 11,349 $ 12,142 Accrued wages and payroll liabilities 199 200 Accrued PBM fees - 571 Customer deposits payable 158 76 Accrued other liabilities 188 187 Total $ 11,894 $ 13,176

Note 15 - Notes Payable

Note 15 - Notes Payable	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 15. Notes payable consisted of the following (in thousands): June 30, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,096 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 204 255 Insurance premiums financing — 103 Subtotal 1,325 1,523 Less: current portion of notes payable (205 ) (312 ) Long-term portion of notes payable $ 1,120 $ 1,211 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of June 30, 2024 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, Bank of England Base Rate July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 In April 2021, September 2021, June 30, 2024 December 31, 2023 In July 2022, January 2023. June 30, 2024 December 31, 2023 In September 2022, October 2022. June 30, 2024 December 31, 2023 Principal outstanding as of June 30, 2024 Year Amount 2024 (remaining six months) $ 115 2025 214 2026 119 2027 124 2028 753 Thereafter - Total $ 1,325

Note 16 - Equity

Note 16 - Equity	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 16. Equity For the six June 30, 2024 2023 no six June 30, 2024 2023 Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No June 30, 2024 no Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of June 30, 2024 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 17. On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 six June 30, 2023 six June 30, 2024 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, June 30, 2024 December 31, 2023

Note 18 - Commitments and Conti

Note 18 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 18. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two October 21, 2024. On June 17, 2024, From time to time, the Company may not no

Note 19 - Leases

Note 19 - Leases	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 19. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 Operating Lease Agreements Right of use ("ROU") assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, June 30, 2024 December 31, 2023 We monitor for events or changes in circumstances that require a reassessment of one On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2025. During June 2023 twenty-five 25 300 June 7, 2023. June 2024

Note 20 - Reportable Segments

Note 20 - Reportable Segments	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 20. The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two The following tables present a summary of the reportable segments (in thousands): For the Three Months Ended June 30, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 10,521 $ - $ 10,521 e-Commerce revenue 3,512 - - 3,512 Pharmacy 340B contract revenue - 2,956 - 2,956 Revenues, net $ 3,512 $ 13,477 $ - $ 16,989 Expenses: Cost of revenue 2,401 8,782 - 11,183 Selling, general and administrative 1,382 895 (60 ) 2,217 Salaries, wages and payroll taxes 619 2,166 - 2,785 Impairment loss - 9,792 - 9,792 Professional fees 620 384 - 1,004 Depreciation and amortization 146 757 - 903 5,168 22,776 (60 ) 27,884 Loss before other (income) expense (1,656 ) (9,299 ) 60 (10,895 ) Other income (210 ) (23 ) (60 ) (173 ) Loss before income taxes (1,446 ) (9,276 ) - (10,722 ) Income taxes (20 ) - - (20 ) Net loss $ (1,466 ) $ (9,276 ) $ - $ (10,742 ) For the Three Months Ended June 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 2,957 - - 2,957 Pharmacy 340B contract revenue - - - - Revenues, net $ 2,957 $ - $ - $ 2,957 Expenses: Cost of revenue 2,113 - - 2,113 Selling, general and administrative 2,519 - - 2,519 Salaries, wages and payroll taxes 968 - - 968 Professional fees 544 - - 544 Depreciation and amortization 168 - - 168 6,312 - - 6,312 Loss before other (income) expense (3,355 ) - - (3,355 ) Other income (473 ) - - (473 ) Loss before income taxes (2,882 ) - - (2,882 ) Income taxes (52 ) - - (52 ) Loss before equity method investment (2,934 ) - - (2,934 ) Equity in net loss of affiliate (1,407 ) - - (1,407 ) Net loss $ (4,341 ) $ - $ - $ (4,341 ) For the Six Months Ended June 30, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 21,773 $ - $ 21,773 e-Commerce revenue 6,377 - - 6,377 Pharmacy 340B contract revenue - 6,332 - 6,332 Revenues, net $ 6,377 $ 28,105 $ - $ 34,482 Expenses: Cost of revenue 4,462 19,405 - 23,867 Selling, general and administrative 2,545 1,795 (120 ) 4,220 Salaries, wages and payroll taxes 1,127 4,282 - 5,409 Impairment loss - 9,924 - 9,924 Professional fees 1,127 862 - 1,989 Depreciation and amortization 277 1,533 - 1,810 9,538 37,801 (120 ) 47,219 Loss before other (income) expense (3,161 ) (9,696 ) 120 (12,737 ) Other income (413 ) (48 ) (120 ) (341 ) Loss before income taxes (2,748 ) (9,648 ) - (12,396 ) Income taxes (47 ) - - (47 ) Net (loss) income $ (2,795 ) $ (9,648 ) $ - $ (12,443 ) For the Six Months Ended June 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 5,834 - - 5,834 Pharmacy 340B contract revenue - - - - Revenues, net $ 5,834 $ - $ - $ 5,834 Expenses: Cost of revenue 4,369 - - 4,369 Selling, general and administrative 3,308 - - 3,308 Salaries, wages and payroll taxes 1,556 - - 1,556 Professional fees 865 - - 865 Depreciation and amortization 330 - - 330 10,428 - - 10,428 Loss before other (income) expense (4,594 ) - - (4,594 ) Other income (558 ) - - (558 ) Loss before income taxes (4,036 ) - - (4,036 ) Income taxes (52 ) - - (52 ) Loss before equity method investment (4,088 ) - - (4,088 ) Equity in net loss of affiliate (1,440 ) - - (1,440 ) Net loss $ (5,528 ) $ - $ - $ (5,528 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of June 30, 2024 $ 39,313 $ 28,827 $ (16,679 ) $ 51,461 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469

Note 21 - Concentrations

Note 21 - Concentrations	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 21. e-Commerce operations concentrations: Customers: Sales to customers through Amazon accounted for 38.4% and 49.1% of the Company’s revenues during the six June 30, 2024 2023 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% three six June 30, 2024 2023 For the Three Months Ended June 30, 2024 For the Three Months Ended June 30, 2023 Iridium Satellite $ 331 13.5 % $ - - % For the Six Months Ended June 30, 2024 For the Six Months Ended June 30, 2023 Iridium Satellite $ 902 19.8 % $ 651 13.4 % Garmin $ 464 10.2 % $ 1,087 22.4 % Geographic The following table sets forth revenue as to each geographic location, for the (in thousands, unaudited): For the Three Months Ended June 30, 2024 For the Three Months Ended June 30, 2023 Europe $ 1,797 51.2 % $ 1,704 57.6 % North America 1,293 36.8 % 870 29.4 % South America 7 0.2 % 8 0.3 % Asia and Pacific 390 11.1 % 335 11.3 % Africa 25 0.7 % 40 1.4 % $ 3,512 100 % $ 2,957 100 % For the Six Months Ended June 30, 2024 For the Six Months Ended June 30, 2023 Europe $ 3,279 51.4 % $ 3,690 63.2 % North America 1,757 27.6 % 1,462 25.1 % South America 30 0.5 % 18 0.3 % Asia and Pacific 803 12.6 % 563 9.7 % Africa 508 8.0 % 101 1.7 % $ 6,377 100 % $ 5,834 100 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98.0% of total vendor purchases for the six June 30, 2024 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Six Months Ended June 30, 2024 A 32 % B 22 % C 18 %

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. On August 11, 2024, three one $350,000 $1,000 $3,000, Rule 10b5 1 During the three June 30, 2024 no 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $4.4 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the six June 30, 2024 six June 30, 2023 December 31, 2023
Revenue from Contract with Customer [Policy Text Block]	Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At June 30, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company has evaluated subsequent events through August 13, 2024

Note 5 - Business Acquisition_2

Note 5 - Business Acquisition - Provisional (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Purchase Price Allocation (in thousands) Total purchase consideration $ 1,094 Identifiable net assets acquired - Provisional: Cash $ 236 Accounts receivable, net 73 Inventory 137 Prepaid expenses 11 Property and equipment, net 5 Right of use assets, net 109 Intangible assets, net: Trade name (1) 185 Customer records (2) 415 Accounts payable and accrued expenses (124 ) Notes payable and accrued interest - current portion (53 ) Lease liabilities - current portion (56 ) Deferred tax liabilities (3) (145 ) Net assets acquired $ 793 Goodwill $ 301

Note 6 - Revenue (Tables)

Note 6 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 10,521 $ - e-Commerce revenue 3,512 2,957 Sub total 14,033 2,957 Revenues from services: Pharmacy 340B contract revenue 2,956 - Revenues, net $ 16,989 $ 2,957 Six Months Ended June 30, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 21,845 $ - e-Commerce revenue 6,377 5,834 Sub total 28,222 5,834 Revenues from services: Pharmacy 340B contract revenue 6,260 - Revenues, net $ 34,482 $ 5,834

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (5,311 ) $ (4,341 ) $ (6,791 ) $ (5,528 ) Basic weighted average common shares outstanding 18,824 18,072 18,774 16,254 Potentially dilutive common shares - - - - Diluted weighted average common shares outstanding 18,824 18,072 18,774 16,254 Weighted average loss per common share - basic and diluted $ (0.28 ) $ (0.24 ) $ (0.36 ) $ (0.34 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 9 240 60 175 Common stock purchase warrants - 1,419 - 583 9 1,659 60 758

Note 8 - Accounts Receivable (T

Note 8 - Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 10,587 $ 9,195 Less: allowance for doubtful accounts (218 ) (272 ) Accounts receivable – trade, net $ 10,369 $ 8,923

Note 9 - Inventory (Tables)

Note 9 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 4,747 $ 5,195 Less reserve for obsolete inventory (46 ) (60 ) Total $ 4,701 $ 5,135

Note 12 - Property and Equipm_2

Note 12 - Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 603 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 172 124 Computer equipment 117 117 Rental equipment 80 60 Appliques 2,160 2,160 Website development 615 587 Construction in progress - 22 Property and equipment gross 6,590 6,492 Less: accumulated depreciation (2,896 ) (2,503 ) Property and equipment, net $ 3,694 $ 3,989

Note 13 - Goodwill and Intang_2

Note 13 - Goodwill and Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Goodwill Reportable Segments [Table Text Block]	e-Commerce Operations Healthcare Operations Total Goodwill, net as of December 31, 2023 $ - $ 731 $ 731 Changes in Goodwill during the year period ended June 30, 2024: Goodwill acquired 301 - 301 Deferred tax effect of intangible basis difference (1) (145 ) - (145 ) Impairment loss - (731 ) (731 ) Goodwill, net as of June 30, 2024 $ 156 $ - $ 156
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 2,447 $ — $ 2,447 Trade names 1,530 — 1,530 Developed technology — — - Customer Contracts 850 (263 ) 587 Total intangible assets $ 4,827 $ (263 ) $ 4,564 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423
Schedule of Intangible Asset Reportable Segments [Table Text Block]	e-Commerce Operations Healthcare Operations Total Balances at December 31, 2023: Gross amount $ 250 $ 15,710 $ 15,960 Accumulated amortization (225 ) (1,312 ) (1,537 ) Net amount 25 14,398 14,423 Changes during the six months ended June 30, 2024: Acquisition 600 — 600 Accumulated amortization expense (38 ) (1,360 ) (1,398 ) Impairment - gross amount — (11,733 ) (11,733 ) Impairment - accumulated amortization — 2,672 2,672 Net amount 562 (10,421 ) (9,859 ) Balances at June 30, 2024: Gross amount 850 3,977 4,827 Accumulated amortization (263 ) — (263 ) Net amount $ 587 $ 3,977 $ 4,564
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amount 2024 (remaining six months) $ 560 2025 1,096 2026 1,096 2027 1,096 2028 600 Thereafter 116 Total $ 4,564

Note 14 - Accounts Payable an_2

Note 14 - Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 11,349 $ 12,142 Accrued wages and payroll liabilities 199 200 Accrued PBM fees - 571 Customer deposits payable 158 76 Accrued other liabilities 188 187 Total $ 11,894 $ 13,176

Note 15 - Notes Payable (Tables

Note 15 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	June 30, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,096 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 204 255 Insurance premiums financing — 103 Subtotal 1,325 1,523 Less: current portion of notes payable (205 ) (312 ) Long-term portion of notes payable $ 1,120 $ 1,211
Schedule of Maturities of Long-Term Debt [Table Text Block]	Year Amount 2024 (remaining six months) $ 115 2025 214 2026 119 2027 124 2028 753 Thereafter - Total $ 1,325

Note 20 - Reportable Segments (

Note 20 - Reportable Segments (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	For the Three Months Ended June 30, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 10,521 $ - $ 10,521 e-Commerce revenue 3,512 - - 3,512 Pharmacy 340B contract revenue - 2,956 - 2,956 Revenues, net $ 3,512 $ 13,477 $ - $ 16,989 Expenses: Cost of revenue 2,401 8,782 - 11,183 Selling, general and administrative 1,382 895 (60 ) 2,217 Salaries, wages and payroll taxes 619 2,166 - 2,785 Impairment loss - 9,792 - 9,792 Professional fees 620 384 - 1,004 Depreciation and amortization 146 757 - 903 5,168 22,776 (60 ) 27,884 Loss before other (income) expense (1,656 ) (9,299 ) 60 (10,895 ) Other income (210 ) (23 ) (60 ) (173 ) Loss before income taxes (1,446 ) (9,276 ) - (10,722 ) Income taxes (20 ) - - (20 ) Net loss $ (1,466 ) $ (9,276 ) $ - $ (10,742 ) For the Three Months Ended June 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 2,957 - - 2,957 Pharmacy 340B contract revenue - - - - Revenues, net $ 2,957 $ - $ - $ 2,957 Expenses: Cost of revenue 2,113 - - 2,113 Selling, general and administrative 2,519 - - 2,519 Salaries, wages and payroll taxes 968 - - 968 Professional fees 544 - - 544 Depreciation and amortization 168 - - 168 6,312 - - 6,312 Loss before other (income) expense (3,355 ) - - (3,355 ) Other income (473 ) - - (473 ) Loss before income taxes (2,882 ) - - (2,882 ) Income taxes (52 ) - - (52 ) Loss before equity method investment (2,934 ) - - (2,934 ) Equity in net loss of affiliate (1,407 ) - - (1,407 ) Net loss $ (4,341 ) $ - $ - $ (4,341 ) For the Six Months Ended June 30, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 21,773 $ - $ 21,773 e-Commerce revenue 6,377 - - 6,377 Pharmacy 340B contract revenue - 6,332 - 6,332 Revenues, net $ 6,377 $ 28,105 $ - $ 34,482 Expenses: Cost of revenue 4,462 19,405 - 23,867 Selling, general and administrative 2,545 1,795 (120 ) 4,220 Salaries, wages and payroll taxes 1,127 4,282 - 5,409 Impairment loss - 9,924 - 9,924 Professional fees 1,127 862 - 1,989 Depreciation and amortization 277 1,533 - 1,810 9,538 37,801 (120 ) 47,219 Loss before other (income) expense (3,161 ) (9,696 ) 120 (12,737 ) Other income (413 ) (48 ) (120 ) (341 ) Loss before income taxes (2,748 ) (9,648 ) - (12,396 ) Income taxes (47 ) - - (47 ) Net (loss) income $ (2,795 ) $ (9,648 ) $ - $ (12,443 ) For the Six Months Ended June 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ - $ - $ - e-Commerce revenue 5,834 - - 5,834 Pharmacy 340B contract revenue - - - - Revenues, net $ 5,834 $ - $ - $ 5,834 Expenses: Cost of revenue 4,369 - - 4,369 Selling, general and administrative 3,308 - - 3,308 Salaries, wages and payroll taxes 1,556 - - 1,556 Professional fees 865 - - 865 Depreciation and amortization 330 - - 330 10,428 - - 10,428 Loss before other (income) expense (4,594 ) - - (4,594 ) Other income (558 ) - - (558 ) Loss before income taxes (4,036 ) - - (4,036 ) Income taxes (52 ) - - (52 ) Loss before equity method investment (4,088 ) - - (4,088 ) Equity in net loss of affiliate (1,440 ) - - (1,440 ) Net loss $ (5,528 ) $ - $ - $ (5,528 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of June 30, 2024 $ 39,313 $ 28,827 $ (16,679 ) $ 51,461 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469

Note 21 - Concentrations (Table

Note 21 - Concentrations (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Three Months Ended June 30, 2024 For the Three Months Ended June 30, 2023 Iridium Satellite $ 331 13.5 % $ - - % For the Six Months Ended June 30, 2024 For the Six Months Ended June 30, 2023 Iridium Satellite $ 902 19.8 % $ 651 13.4 % Garmin $ 464 10.2 % $ 1,087 22.4 % For the Three Months Ended June 30, 2024 For the Three Months Ended June 30, 2023 Europe $ 1,797 51.2 % $ 1,704 57.6 % North America 1,293 36.8 % 870 29.4 % South America 7 0.2 % 8 0.3 % Asia and Pacific 390 11.1 % 335 11.3 % Africa 25 0.7 % 40 1.4 % $ 3,512 100 % $ 2,957 100 % For the Six Months Ended June 30, 2024 For the Six Months Ended June 30, 2023 Europe $ 3,279 51.4 % $ 3,690 63.2 % North America 1,757 27.6 % 1,462 25.1 % South America 30 0.5 % 18 0.3 % Asia and Pacific 803 12.6 % 563 9.7 % Africa 508 8.0 % 101 1.7 % $ 6,377 100 % $ 5,834 100 % Six Months Ended June 30, 2024 A 32 % B 22 % C 18 %

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Operations. (Details Textual)	Jun. 30, 2024	Apr. 01, 2024	Dec. 06, 2023
Outfitter Satellite, Inc. [Member]
Subsidiary, Ownership Percentage, Parent		100%
Pharmco 901 [Member] | Progressive Care [Member]
Subsidiary, Ownership Percentage, Parent	100%
Florida Sunshine Brands, LLC [Member]
Subsidiary, Ownership Percentage, Parent			51%
Florida Sunshine Brands, LLC [Member] | Outer Brands FS, LLC [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			49%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Principles of Consolidation (Details Textual)	Jul. 01, 2023
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2023
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	4,400,000
Contract with Customer, Liability	$ 142,000	$ 42,000
Closing Rate [Member]
Foreign Currency Exchange Rate, Translation	1.28	1.27	1.23
Yearly Average Rate [Member]
Foreign Currency Exchange Rate, Translation	1.27	1.24	1.22
Maximum [Member]
Cash, FDIC Insured Amount	$ 250,000

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Millions	Apr. 01, 2024	Jul. 01, 2023
Progressive Care [Member]
Finite-Lived Intangible Assets, Fair Value Disclosure		$ 14.7
Outfitter Satellite, Inc. [Member]
Finite-Lived Intangible Assets, Fair Value Disclosure	$ 0.6

Note 5 - Business Acquisition_3

Note 5 - Business Acquisition - Provisional (Details Textual) $ in Thousands			6 Months Ended
		Jan. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Apr. 01, 2024 USD ($)
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)			4 years
Finite-Lived Intangible Assets Acquired			$ 600
Outfitter Satellite, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	[1]			$ 145
Finite-Lived Intangible Assets Acquired		$ 600
Outfitter Satellite, Inc. [Member] | Measurement Input, Discount Rate [Member]
Intangible Assets, Measurement Input		0.373
Outfitter Satellite, Inc. [Member] | Measurement Input, Assumed Capitalization Rate [Member]
Intangible Assets, Measurement Input		0.343
Outfitter Satellite, Inc. [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member]
Intangible Assets, Measurement Input		0.03	0.03
Outfitter Satellite, Inc. [Member] | Measurement Input, Assumed Royalty Rate [Member]
Intangible Assets, Measurement Input		0.018
Outfitter Satellite, Inc. [Member] | Measurement Input, Assumed Tax Rate [Member]
Intangible Assets, Measurement Input		0.263
Outfitter Satellite, Inc. [Member] | Measurement Input, Risk Free Interest Rate [Member]
Intangible Assets, Measurement Input		0.045
Outfitter Satellite, Inc. [Member] | Measurement Input, Assumed Equity Risk Premium [Member]
Intangible Assets, Measurement Input		0.065
Outfitter Satellite, Inc. [Member] | Measurement Input, Company Specific Risk Premium Rate [Member]
Intangible Assets, Measurement Input		0.225
Outfitter Satellite, Inc. [Member] | Measurement Input, Assumed Beta [Member]
Intangible Assets, Measurement Input		0.82
Outfitter Satellite, Inc. [Member] | Scenario, Adjustment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities				$ 100
Trade Names [Member]
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)				10 years
Customer Lists [Member]
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)				5 years
[1]Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference at April 1, 2024, the date of the business combination transaction. Therefore, an approximate $0.1 million deferred tax liability was recorded at April 1, 2024 as a result of the book/tax basis difference for the finite lived intangible assets.

Note 5 - Business Acquisition_4

Note 5 - Business Acquisition - Provisional - Summary of Consideration Transferred in Business Acquisition (Details) - USD ($) $ in Thousands		Apr. 01, 2024	Jun. 30, 2024	Dec. 31, 2023
Goodwill			$ 156	$ 731
Outfitter Satellite, Inc. [Member]
Total purchase consideration		$ 1,094
Cash		236
Accounts receivable, net		73
Inventory		137
Prepaid expenses		11
Property and equipment, net		5
Right of use assets, net		109
Accounts payable and accrued expenses		(124)
Notes payable and accrued interest - current portion		(53)
Lease liabilities - current portion		(56)
Deferred tax liabilities (3)	[1]	(145)
Net assets acquired		793
Goodwill		301
Outfitter Satellite, Inc. [Member] | Trade Names [Member]
Finite-Lived Intangibles	[2]	185
Outfitter Satellite, Inc. [Member] | Customer Lists [Member]
Finite-Lived Intangibles	[3]	$ 415
[1]Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference at April 1, 2024, the date of the business combination transaction. Therefore, an approximate $0.1 million deferred tax liability was recorded at April 1, 2024 as a result of the book/tax basis difference for the finite lived intangible assets.[2]10 year amortization period[3]5 year amortization period

Note 6 - Revenue - Disaggregati

Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 16,989	$ 2,957	$ 34,482	$ 5,834
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	10,521	0	21,773	0
Pharmacy 340B Contract [Member]
Revenue	2,956	0	6,332	0
E-Commerce Revenue [Member]
Revenue	16,989		34,482
E-Commerce Revenue [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	10,521		21,845
E-Commerce Revenue [Member] | E-Commerce [Member]
Revenue	3,512		6,377
E-Commerce Revenue [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue	14,033		28,222
E-Commerce Revenue [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 2,956		$ 6,260
Healthcare Operations [Member]
Revenue		2,957		5,834
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0		0
Healthcare Operations [Member] | E-Commerce [Member]
Revenue		2,957		5,834
Healthcare Operations [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue		2,957		5,834
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		$ 0		$ 0

Note 7 - Loss Per Share - Earni

Note 7 - Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss attributable to NextPlat Corp common shareholders	$ (5,311)	$ (4,341)	$ (6,791)	$ (5,528)
Basic weighted average common shares outstanding (in shares)	18,824	18,072	18,774	16,254
Potentially dilutive common shares (in shares)	0	0	0	0
Diluted weighted average common shares outstanding (in shares)	18,824	18,072	18,774	16,254
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.28)	$ (0.24)	$ (0.36)	$ (0.34)
Antidilutive securities (in shares)	9	1,659	60	758
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	9	240	60	175
Warrant [Member]
Antidilutive securities (in shares)	0	1,419	0	583

Note 8 - Accounts Receivable (D

Note 8 - Accounts Receivable (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ (54,000)	$ 0
Accounts Receivable, after Allowance for Credit Loss	$ 10,369,000	$ 600,000	$ 8,923,000	$ 400,000

Note 8 - Accounts Receivable -

Note 8 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Jan. 01, 2023
Gross accounts receivable – trade	$ 10,587	$ 9,195
Less: allowance for doubtful accounts	(218)	(272)
Accounts receivable – trade, net	$ 10,369	$ 8,923	$ 600	$ 400

Note 9 - Inventory - Summary of

Note 9 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Finished goods	$ 4,747	$ 5,195
Less reserve for obsolete inventory	(46)	(60)
Total	$ 4,701	$ 5,135

Note 10 - VAT Receivable (Detai

Note 10 - VAT Receivable (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Value Added Tax Receivable, Current	$ 333,000	$ 342,000

Note 11 - Prepaid Expenses (Det

Note 11 - Prepaid Expenses (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Prepaid Expense, Current	$ 273,000	$ 640,000
Prepaid Expense, Noncurrent	$ 66,000	$ 61,000

Note 12 - Property and Equipm_3

Note 12 - Property and Equipment, Net (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation	$ 399,000	$ 317,000

Note 12 - Property and Equipm_4

Note 12 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment gross	$ 6,590	$ 6,492
Less: accumulated depreciation	(2,896)	(2,503)
Property and equipment, net	3,694	3,989
Building [Member]
Property and equipment gross	2,116	2,116
Vehicles [Member]
Property and equipment gross	603	595
Furniture and Fixtures [Member]
Property and equipment gross	543	527
Land [Member]
Property and equipment gross	184	184
Leasehold Improvements [Member]
Property and equipment gross	172	124
Computer Equipment [Member]
Property and equipment gross	117	117
Rental Equipment [Member]
Property and equipment gross	80	60
Appliques [Member]
Property and equipment gross	2,160	2,160
Website Development [Member]
Property and equipment gross	615	587
Construction in Progress [Member]
Property and equipment gross	$ 0	$ 22

Note 13 - Goodwill and Intang_3

Note 13 - Goodwill and Intangible Assets, net (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Apr. 01, 2024	Mar. 31, 2024	Jan. 01, 2024
Goodwill, Impairment Loss		$ 731,000
Impairment of Intangible Assets, Finite-Lived		$ (9,859,000)
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)	4 years	4 years
Amortization of Intangible Assets		$ 1,398,000	$ 12,500
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years	5 years			10 years
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)				10 years
Pharmacy Records [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years	5 years
Outfitter Satellite, Inc. [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member]
Intangible Assets, Measurement Input	0.03	0.03				0.03
Outfitter Satellite, Inc. [Member] | Measurement Input, Weighted Average Cost of Capital [Member]
Intangible Assets, Measurement Input	0.135	0.135
Healthcare Operations [Member]
Goodwill, Impairment Loss		$ 700,000
Impairment of Intangible Assets, Finite-Lived	$ 9,100,000

Note 13 - Goodwill and Intang_4

Note 13 - Goodwill and Intangible Assets, Net - Schedule of Goodwill Reportable Segments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill	$ 731
Goodwill acquired	301
Deferred tax effect of intangible basis difference (1)	(145)	[1]
Impairment loss	(731)
Goodwill	156
E-Commerce Operations [Member]
Goodwill	0
Goodwill acquired	301
Deferred tax effect of intangible basis difference (1)	(145)	[1]
Impairment loss	0
Goodwill	156
Healthcare Operations [Member]
Goodwill	731
Goodwill acquired	0
Deferred tax effect of intangible basis difference (1)	0	[1]
Impairment loss	(731)
Goodwill	$ 0
[1]Decrease related to book tax basis difference of intangible assets arising for the business acquisition of Outfitter.

Note 13 - Goodwill and Intang_5

Note 13 - Goodwill and Intangible Assets, Net - Summary of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jan. 01, 2024	Dec. 31, 2023
Gross amount	$ 4,827	$ 15,960	$ 15,960
Accumulated amortization	(263)	(1,537)	(1,537)
Net amount	4,564	$ 14,423	14,423
Pharmacy Records [Member]
Gross amount	2,447		8,130
Accumulated amortization	0		(807)
Net amount	2,447		7,323
Trade Names [Member]
Gross amount	1,530		4,700
Accumulated amortization	0		(224)
Net amount	1,530		4,476
Computer Software, Intangible Asset [Member]
Gross amount	0		2,880
Accumulated amortization	0		(281)
Net amount	0		2,599
Customer Contracts [Member]
Gross amount	850		250
Accumulated amortization	(263)		(225)
Net amount	$ 587		$ 25

Note 13 - Goodwill and Intang_6

Note 13 - Goodwill and Intangible Assets, Net - Schedule of Intangible Asset Reportable Segments (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jan. 01, 2024	Dec. 31, 2023
Gross amount	$ 4,827,000		$ 15,960,000	$ 15,960,000
Accumulated amortization	(263,000)		(1,537,000)	(1,537,000)
Net amount	4,564,000		14,423,000	$ 14,423,000
Acquisition	600,000
Accumulated amortization expense	(1,398,000)	$ (12,500)
Impairment - gross amount	(11,733,000)
Impairment - accumulated amortization	2,672,000
Impairment - net	(9,859,000)
E-Commerce Operations [Member]
Gross amount	850,000		250,000
Accumulated amortization	(263,000)		(225,000)
Net amount	587,000		25,000
Acquisition	600,000
Accumulated amortization expense	(38,000)
Impairment - gross amount	0
Impairment - accumulated amortization	0
Impairment - net	562,000
Healthcare Operations [Member]
Gross amount	3,977,000		15,710,000
Accumulated amortization	0		(1,312,000)
Net amount	3,977,000		$ 14,398,000
Acquisition	0
Accumulated amortization expense	(1,360,000)
Impairment - gross amount	(11,733,000)
Impairment - accumulated amortization	2,672,000
Impairment - net	$ (10,421,000)

Note 13 - Goodwill and Intang_7

Note 13 - Goodwill and Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jan. 01, 2024	Dec. 31, 2023
2024 (remaining six months)	$ 560
2025	1,096
2026	1,096
2027	1,096
2028	600
Thereafter	116
Total	$ 4,564	$ 14,423	$ 14,423

Note 14 - Accounts Payable an_3

Note 14 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts payable	$ 11,349	$ 12,142
Accrued wages and payroll liabilities	199	200
Accrued PBM fees	0	571
Customer deposits payable	158	76
Accrued other liabilities	188	187
Total	$ 11,894	$ 13,176

Note 15 - Notes Payable (Detail

Note 15 - Notes Payable (Details Textual)		1 Months Ended			12 Months Ended
	Jul. 16, 2020 GBP (£)	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 16, 2020 USD ($)	Jul. 16, 2020 GBP (£)
Long-Term Debt						$ 1,325,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Base Rate [Member]
Collateralized Promissory Note [Member] | Progressive Care [Member]
Debt Instrument, Face Amount					$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Debt Instrument, Number of Payments					119
Debt Instrument, Periodic Payment					$ 11,901
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member]
Debt Instrument, Face Amount								$ 338,343	£ 250,000
Foreign Currency Exchange Rate, Translation								1.353372	1.353372
Debt Instrument, Basis Spread on Variable Rate	4%
Debt Instrument, Interest Rate, Effective Percentage								0.10%	0.10%
Debt Instrument, Term (Year)	6 years
Debt Instrument, Periodic Payment, Principal | £	£ 4,166.67
Debt Instrument, Prepayment Limit, Percentage of Balance of Debenture								10%	10%
Note Obligation for Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount				$ 30,000
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Debt Instrument, Number of Payments				46
Debt Instrument, Periodic Payment				$ 331
Long-Term Debt						65,000	$ 71,000
Amended Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Long-Term Debt						4,000	6,500
Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount			$ 90,000
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Debt Instrument, Number of Payments			60
Debt Instrument, Periodic Payment			$ 1,859
Note Obligation for Vehicles [Member] | Progressive Care [Member]
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Debt Instrument, Number of Payments		24
Debt Instrument, Periodic Payment		$ 1,143
Long-Term Debt						$ 3,000	$ 10,000

Note 15 - Notes Payable - Sched

Note 15 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Note payable	$ 1,325	$ 1,523
Less: current portion of notes payable	(205)	(312)
Long-term portion of notes payable	1,120	1,211
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,096	1,140
Note Payable Uncollateralized [Member]
Note payable	25	25
Note Payable Collateralized [Member]
Note payable	204	255
Insurance Premium Financing [Member]
Note payable	$ 0	$ 103

Note 15 - Notes Payable - Sch_2

Note 15 - Notes Payable - Schedule of Future Maturities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2024 (remaining six months)	$ 115
2025	214
2026	119
2027	124
2028	753
Thereafter	0
Total	$ 1,325

Note 16 - Equity (Details Textu

Note 16 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Apr. 11, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Share-Based Payment Arrangement, Expense		$ 1,200	$ 2,000
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 0	$ 0
Preferred Stock, Shares Authorized (in shares)		3,333,333		3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Preferred Stock, Shares Outstanding (in shares)		0
Common Stock, Shares Authorized (in shares)		50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Common Stock, Shares, Issued (in shares)		18,973,146		18,724,596
Preferred Stock, Shares Issued (in shares)		0
Common Stock, Shares, Outstanding (in shares)		18,973,146		18,724,596
April 2023 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	3,428,571
Shares Issued, Price Per Share (in dollars per share)	$ 1.75
Proceeds from Issuance of Private Placement	$ 6,000

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual)

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 07, 2023 USD ($)

Jul. 01, 2023 USD ($) shares

May 09, 2023 shares

May 01, 2023 USD ($)

Feb. 01, 2023 USD ($)

Dec. 30, 2022

Sep. 02, 2022 USD ($)

Jul. 12, 2022 USD ($)

Apr. 30, 2023 USD ($)

Mar. 31, 2023 USD ($)

Jun. 30, 2024 USD ($) $ / shares

Jun. 30, 2023 USD ($)

Dec. 31, 2023 USD ($) $ / shares

May 05, 2023 USD ($) $ / shares shares

Aug. 30, 2022 USD ($) shares

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Proceeds from Warrant Exercises | $

$ 85,000

$ 184,000

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

200

Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

105,000

Progressive Care [Member]

Investment Owned, Balance, Shares (in shares) | shares

402,269

455,000

Investment Owned, Price Per Share (in dollars per share) | $ / shares

$ 2.2

Investment Owned, Cost | $

$ 1,000,000

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

Proceeds from Warrant Exercises | $

$ 506,000

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

230,000

Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 1,000,000

Debt Conversion Agreement [Member] | Predecessor Company [Member]

Long-Term Debt, Gross | $

$ 2,800,000

Lauren Sturges Fernandez [Member]

Annual Salary | $

$ 95,000

$ 125,000

Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold | $

$ 10,995

CEO and Board Member [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable, Including Contributions by Related Parties | $

2,300,000

Chief Operating Officer [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 400,000

NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

570,599

NextPlat Corp [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

45,653

Chief Executive Officer [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

190,000

Chief Executive Officer [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

228,240

Chief Executive Officer [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

18,261

Chief Executive Officer [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

211,470

Board Member [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

30,000

Board Member [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

228,240

Board Member [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

18,261

Board Member [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

130,571

Progressive Care [Member]

Management and Administrative Service Revenue, Per Month | $

$ 20,000

$ 25,000

Proceeds From Management and Administrative Service | $

120,000

$ 115,000

Fernandez And Barreto [Member] | Progressive Care [Member]

Related Party, Ownership Percentage

53%

Related Party [Member]

Notes Receivable, Principal | $

$ 250,000

Notes Receivable, Interest Rate

7%

Financing Receivable, before Allowance for Credit Loss | $

$ 265,000

$ 256,000

Note 19 - Leases (Details Textu

Note 19 - Leases (Details Textual)			1 Months Ended				3 Months Ended		6 Months Ended	12 Months Ended
	Dec. 02, 2021 USD ($) ft²	May 31, 2018 USD ($)	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2023 USD ($)	Sep. 30, 2021 USD ($)	Aug. 31, 2020 USD ($)	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2024 GBP (£) ft²	Jun. 30, 2024 USD ($) ft²	Dec. 31, 2023 USD ($)
Operating Lease, Impairment Loss									$ 132,000	$ 0
Office Space in Florida [Member]
Lessee, Operating Lease, Term of Contract (Month)	62 months
Area of Real Estate Property (Square Foot) | ft²	4,141
Annual Rent	$ 186,345
Annual Lease Increase, Percentage	3%
Facilities in Poole, England [Member]
Area of Real Estate Property (Square Foot) | ft²			2,660				2,660	2,660	2,660
Annual Rent							$ 37,107	£ 30,000
Foreign Currency Exchange Rate, Translation			1.24				1.24	1.24	1.24
Lessee, Operating Lease, Renewal Term (Month)			12 months				12 months	12 months	12 months
Aircraft Lease [Member]
Lessee, Operating Lease, Term of Contract (Month)				36 years
Annual Lease Increase, Percentage				3%
Operating Lease, Monthly Payment				$ 200,650
Operating Lease, Termination Fee			$ 100,000
Aircraft Lease [Member] | Selling, General and Administrative Expenses [Member]
Operating Lease, Termination, Remaining Carrying Value, Write-Off			$ 100,000
Progressive Care [Member] | Finance Obligation for Pharmacy Equipment [Member]
Finance Lease, Liability		$ 115,000
Finance Lease, Monthly Payment		$ 1,678
Lessee, Finance Lease, Term of Contract (Month)		84 months
Lessee, Finance Lease, Interest Rate		6%
Progressive Care [Member] | Orlando Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)						66 months
Operating Lease, Monthly Payment						$ 4,310
Progressive Care [Member] | North Miami Beach Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)					60 months
Operating Lease, Monthly Payment					$ 5,237

Note 20 - Reportable Segments_2

Note 20 - Reportable Segments (Details Textual)	6 Months Ended
	Jun. 30, 2024
Number of Reportable Segments	2

Note 20 - Reportable Segments -

Note 20 - Reportable Segments - Schedule of Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 16,989		$ 2,957		$ 34,482	$ 5,834
Cost of revenue	11,183		2,113		23,867	4,369
Selling, general and administrative	2,218		2,519		4,220	3,308
Salaries, wages and payroll taxes	2,785		968		5,409	1,556
Impairment loss	9,792		0		9,924	0
Professional fees	1,004		544		1,989	865
Depreciation and amortization	903		168		1,810	330
Expenses, Including Cost of Revenue	27,884		6,312		47,219	10,428
Loss before other (income) expense	(10,896)		(3,355)		(12,737)	(4,594)
Other income	(173)		(473)		(341)	(558)
Loss before income taxes	(10,723)		(2,882)		(12,396)	(4,036)
Income taxes	(20)		(52)		(47)	(52)
Net loss	(10,743)	$ (1,701)	(4,341)	$ (1,187)	(12,443)	(5,528)
Loss before equity method investment	(10,743)		(2,934)		(12,443)	(4,088)
Equity in net loss of affiliate	0		(1,407)		0	(1,440)
Approximation [Member]
Loss before other (income) expense	(10,895)
Loss before income taxes	(10,722)
Net loss	(10,742)
Segment Expense [Member]
Selling, general and administrative	2,217		2,519		4,220	3,308
Professional fees	1,004		544		1,989	865
Depreciation and amortization	903		168		1,810	330
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	10,521		0		21,773	0
E-Commerce Revenue [Member]
Revenue	3,512		2,957		6,377	5,834
Pharmacy 340B Contract [Member]
Revenue	2,956		0		6,332	0
Consolidation, Eliminations [Member]
Revenue	0		0		0	0
Cost of revenue	0		0		0	0
Salaries, wages and payroll taxes	0		0		0	0
Impairment loss	0				0
Expenses, Including Cost of Revenue	(60)		0		(120)	0
Loss before other (income) expense	60		0		120	0
Other income	(60)		0		(120)	0
Loss before income taxes	0		0		0	0
Income taxes	0		0		0	0
Net loss	0		0		0	0
Loss before equity method investment			0			0
Equity in net loss of affiliate			0			0
Consolidation, Eliminations [Member] | Segment Expense [Member]
Selling, general and administrative	(60)		0		(120)	0
Professional fees	0		0		0	0
Depreciation and amortization	0		0		0	0
Consolidation, Eliminations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0		0		0	0
Consolidation, Eliminations [Member] | E-Commerce Revenue [Member]
Revenue	0		0		0	0
Consolidation, Eliminations [Member] | Pharmacy 340B Contract [Member]
Revenue	0		0		0	0
E-Commerce [Member] | Operating Segments [Member]
Revenue	3,512		2,957		6,377	5,834
Cost of revenue	2,401		2,113		4,462	4,369
Salaries, wages and payroll taxes	619		968		1,127	1,556
Impairment loss	0				0
Expenses, Including Cost of Revenue	5,168		6,312		9,538	10,428
Loss before other (income) expense	(1,656)		(3,355)		(3,161)	(4,594)
Other income	(210)		(473)		(413)	(558)
Loss before income taxes	(1,446)		(2,882)		(2,748)	(4,036)
Income taxes	(20)		(52)		(47)	(52)
Net loss	(1,466)		(4,341)		(2,795)	(5,528)
Loss before equity method investment			(2,934)			(4,088)
Equity in net loss of affiliate			(1,407)			(1,440)
E-Commerce [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	1,382		2,519		2,545	3,308
Professional fees	620		544		1,127	865
Depreciation and amortization	146		168		277	330
E-Commerce [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0		0		0	0
E-Commerce [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	3,512		2,957		6,377	5,834
E-Commerce [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	0		0		0	0
Healthcare Operations [Member]
Revenue			2,957			5,834
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue			0			0
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue			0			0
Healthcare Operations [Member] | Operating Segments [Member]
Revenue	13,477		0		28,105	0
Cost of revenue	8,782		0		19,405	0
Salaries, wages and payroll taxes	2,166		0		4,282	0
Impairment loss	9,792				9,924
Expenses, Including Cost of Revenue	22,776		0		37,801	0
Loss before other (income) expense	(9,299)		0		(9,696)	0
Other income	(23)		0		(48)	0
Loss before income taxes	(9,276)		0		(9,648)	0
Income taxes	0		0		0	0
Net loss	(9,276)		0		(9,648)	0
Loss before equity method investment			0			0
Equity in net loss of affiliate			0			0
Healthcare Operations [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	895		0		1,795	0
Professional fees	384		0		862	0
Depreciation and amortization	757		0		1,533	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	10,521		0		21,773	0
Healthcare Operations [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	0		0		0	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 2,956		$ 0		$ 6,332	$ 0

Note 20 - Reportable Segments_3

Note 20 - Reportable Segments - Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Total Assets	$ 51,461	$ 64,469
Operating Segments [Member] | E-Commerce [Member]
Total Assets	39,313	40,764
Operating Segments [Member] | Healthcare Operations [Member]
Total Assets	28,827	40,384
Consolidation, Eliminations [Member]
Total Assets	$ (16,679)	$ (16,679)

Note 21 - Concentrations (Detai

Note 21 - Concentrations (Details Textual)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Amazon [Member]
Concentration Risk, Percentage	38.40%	49.10%
Purchases [Member] | Supplier Concentration Risk [Member]
Number of Major Vendors	1
Purchases [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%

Note 21 - Concentrations - Sche

Note 21 - Concentrations - Schedules of Concentration of Risk (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 16,989	$ 2,957	$ 34,482	$ 5,834
Purchases [Member] | Supplier Concentration Risk [Member] | Iridium Satellite [Member]
Purchases	$ 331	$ 0	$ 464	$ 1,087
Percentage	13.50%	0%	10.20%	22.40%
Purchases [Member] | Supplier Concentration Risk [Member] | Garmin [Member]
Purchases			$ 902	$ 651
Percentage			19.80%	13.40%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Percentage	51.20%	57.60%	51.40%	63.20%
Revenue	$ 1,797	$ 1,704	$ 3,279	$ 3,690
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | North America [Member]
Percentage	36.80%	29.40%	27.60%	25.10%
Revenue	$ 1,293	$ 870	$ 1,757	$ 1,462
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | South America [Member]
Percentage	0.20%	0.30%	0.50%	0.30%
Revenue	$ 7	$ 8	$ 30	$ 18
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Asia Pacific [Member]
Percentage	11.10%	11.30%	12.60%	9.70%
Revenue	$ 390	$ 335	$ 803	$ 563
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Africa [Member]
Percentage	0.70%	1.40%	8%	1.70%
Revenue	$ 25	$ 40	$ 508	$ 101
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | All Countries [Member]
Percentage	100%	100%	100%	100%
Revenue	$ 3,512	$ 2,957	$ 6,377	$ 5,834
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM A [Member]
Percentage			32%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM B [Member]
Percentage			22%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM C [Member]
Percentage			18%